Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide plus hydroxyurea for pediatric β‑thalassemia
ChiCTR2100054610Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Dec 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide and hydroxyurea in beta thalassemia, beta thalassemia major and beta-thalassemia intermedia, sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Transfusion volume. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
thalidomidehydroxyurea
03
Conditions
beta thalassemiabeta thalassemia majorbeta-thalassemia intermedia
Beyond the preview
Go deeper on ChiCTR2100054610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054610.